Larimar Therapeutics (LRMR)
(Real Time Quote from BATS)
$7.56 USD
+0.41 (5.73%)
Updated Aug 8, 2024 01:44 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LRMR 7.56 +0.41(5.73%)
Will LRMR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LRMR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LRMR
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
LRMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study
Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat
Larimar (LRMR) Upgraded to Strong Buy: What Does It Mean for the Stock?
Other News for LRMR
Commit To Purchase Larimar Therapeutics At $5, Earn 20.3% Annualized Using Options
Larimar Therapeutics GAAP EPS of -$0.34
Larimar: Q2 Earnings Snapshot
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Larimar Therapeutics plans PK run-in study in adolescents, children with FA